Todd Bradley

Todd Bradley

Auto-generated profile, based on publicly available information

Todd Bradley

Genomic Medicine Center, Children’s Mercy Research Institute, Kansas City, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2019 in Science
Verified
Journal Article
Closed access
PDF file
KSKevin O. Saunders
Kevin O. Saunders
KWKevin Wiehe
Kevin Wiehe
MTMing Tian
Ming Tian
PAPriyamvada Acharya
Priyamvada Acharya
TBTodd Bradley
Todd Bradley
BHBarton F. Haynes
Barton F. Haynes
Engineering better bnAbs: A highly effective HIV vaccine has been the goal of vaccinologists for nearly 35 years. A successful vaccine would need to induce broadly neutralizing antibodies (bnAbs) that are capable of neutralizing multiple HIV strains (see the Perspective by Agazio and Torres). Steichen et al. report a strategy in which the first vaccine shot can lead to immune responses that generate desired bnAbs. By combining knowledge of human antibody repertoires and structure to guide design, they validated candidate immunogens through functional preclinical testing. Saunders et al. designed immunogens with differences in binding strength for bnAb precursors, which enabled selection of rare mutations after immunization. The immunogens promoted bnAb precursor maturation in humanized mice and macaques. Science , this issue p. eaax4380 , p. eaay7199 ; see also p. 1197

20 May 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TBTodd Bradley
Todd Bradley
EGElin Grundberg
Elin Grundberg
RSRangaraj Selvarangan
Rangaraj Selvarangan
CLCas LeMaster
Cas LeMaster
EFElizabeth Fraley
Elizabeth Fraley
JSJennifer Schuster
Jennifer Schuster
Currently, two vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that involve messenger RNA (mRNA) platform technology have been approved for emergency use by the Food and Drug Administration (FDA) (mRNA-1273, Moderna; and BNT162b2, Pfizer).1,2 Phase 3 trials of these vaccines showed greater than 90% efficacy at preventing symptomatic infection after two doses administered 3 to 4 weeks apart. These trials primarily involved participants without previous SARS-CoV-2 infection. More than 26 million cases of coronavirus disease 2019 (Covid-19) have been documented in the United States, and high rates of seropositivity have been observed in recent studies.3 Thus, the immune response to vaccination in persons with previous SARS-CoV-2 infection needs to be defined.

26 July 2021 in BMC Medicine
Verified
Journal Article
Open access
PDF file
EFElizabeth Fraley
Elizabeth Fraley
CLCas LeMaster
Cas LeMaster
EGEric Geanes
Eric Geanes
DBDithi Banerjee
Dithi Banerjee
SKSantosh Khanal
Santosh Khanal
TBTodd Bradley
Todd Bradley
Background: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by infection with the SARS-CoV-2 virus. Currently, there are three approved vaccines against SARS-CoV-2 in the USA, including two based on messenger RNA (mRNA) technology that has demonstrated high vaccine efficacy. We sought to characterize humoral immune responses, at high resolution, during immunization with the BNT162b2 (Pfizer-BioNTech) vaccine in individuals with or without prior history of natural SARS-CoV-2 infection. Methods: We determined antibody responses after each dose of the BNT162b2 SARS-CoV-2 vaccine in individuals who had no prior history of SARS-CoV-2 infection (seronegative) and individuals that had previous viral infection 30–60 days prior to first vaccination (seropositive). To do this, we used both an antibody isotype-specific multiplexed bead-based binding assays targeting multiple SARS-CoV-2 viral protein antigens and an assay that identified potential SARS-CoV-2 neutralizing antibody levels. Moreover, we mapped antibody epitope specificity after immunization using SARS-CoV-2 spike protein peptide arrays. Results: Antibody levels were significantly higher after a single dose in seropositive individuals compared to seronegative individuals and were comparable to levels observed in seronegative individuals after two doses. While IgG was boosted by vaccination for both seronegative and seropositive individuals, only seronegative individuals had increased IgA or IgM antibody titers after primary immunization. We identified immunodominant peptides targeted on both SARS-CoV-2 spike S1 and S2 subunits after vaccination. Conclusion: These findings demonstrated the antibody responses to SARS-CoV-2 immunization in seropositive and seronegative individuals and provide support for the concept of using prior infection history as a guide for the consideration of future vaccination regimens. Moreover, we identified key epitopes on the SARS-CoV-2 spike protein that are targeted by antibodies after vaccination that could guide future vaccine and immune correlate development.

31 May 2021 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
EFElizabeth Fraley
Elizabeth Fraley
CLCas LeMaster
Cas LeMaster
DBDithi Banerjee
Dithi Banerjee
SKSantosh Khanal
Santosh Khanal
RSRangaraj Selvarangan
Rangaraj Selvarangan
TBTodd Bradley
Todd Bradley

20 April 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EGEric Geanes
Eric Geanes
CLCas LeMaster
Cas LeMaster
EFElizabeth R. Fraley
Elizabeth R. Fraley
SKSantosh Khanal
Santosh Khanal
RMRebecca McLennan
Rebecca McLennan
TBTodd Bradley
Todd Bradley
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has resulted in millions of deaths worldwide. Novel coronavirus infections in humans have steadily become more common. Understanding antibody responses to SARS-CoV-2, and identifying conserved, cross-reactive epitopes among coronavirus strains could inform the design of vaccines and therapeutics with broad application. Here, we determined that individuals with previous SARS-CoV-2 infection or vaccinated with the Pfizer-BioNTech BNT162b2 vaccine produced antibody responses that cross-reacted with related betacoronaviruses. Moreover, we designed a peptide-conjugate vaccine with a conserved SARS-CoV-2 S2 spike epitope, immunized mice and determined cross-reactive antibody binding to SARS-CoV-2 and other related coronaviruses. This conserved spike epitope also shared sequence homology to proteins in commensal gut microbiota and could prime immune responses in humans. Thus, SARS-CoV-2 conserved epitopes elicit cross-reactive immune responses to both related coronaviruses and host bacteria that could serve as future targets for broad coronavirus therapeutics and vaccines.

19 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TBTodd Bradley
Todd Bradley
MKMasayuki Kuraoka
Masayuki Kuraoka
CYChen-Hao Yeh
Chen-Hao Yeh
MTMing Tian
Ming Tian
HCHuan Chen
Huan Chen
BHBarton F. Haynes
Barton F. Haynes
Eliciting protective titers of HIV-1 broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development, but current vaccine strategies have yet to induce bnAbs in humans. Many bnAbs isolated from HIV-1-infected individuals are encoded by immunoglobulin gene rearrangments with infrequent naive B cell precursors and with unusual genetic features that may be subject to host regulatory control. Here, we administer antibodies targeting immune cell regulatory receptors CTLA-4, PD-1 or OX40 along with HIV envelope (Env) vaccines to rhesus macaques and bnAb immunoglobulin knock-in (KI) mice expressing diverse precursors of CD4 binding site HIV-1 bnAbs. CTLA-4 blockade augments HIV-1 Env antibody responses in macaques, and in a bnAb-precursor mouse model, CTLA-4 blocking or OX40 agonist antibodies increase germinal center B and T follicular helper cells and plasma neutralizing antibodies. Thus, modulation of CTLA-4 or OX40 immune checkpoints during vaccination can promote germinal center activity and enhance HIV-1 Env antibody responses.